GSK (GSK) said Monday it completed its acquisition of Boston Pharmaceuticals' steatotic liver disease therapeutic candidate efimosfermin.
As part of the deal that was first announced in May, GSK has acquired Boston Pharmaceuticals' BP Asset IX subsidiary for an upfront payment of $1.2 billion and up to $800 million in success-based milestone payments. The drugmaker also said it will be responsible to provide Novartis (NVS) with milestone payments as well as royalties relating to efimosfermin.
Efimosfermin is a once-monthly fibroblast growth factor 21 analog in development for metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease, GSK said.
GSK said the drug's antifibrotic mechanism may make it suitable for more advanced stages of liver disease and sees future combination potential with its GSK'990 therapeutic.
Price: 38.32, Change: +0.14, Percent Change: +0.37
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。